EWSR1 and neoplasm: After defining the genomic breakpoint of EWS-WT1 fusion, DSRCT patients can benefit from a highly specific test that has the advantage of a rapid turnaround time and potentially higher sensitivity in detecting disease progression earlier than imaging exams or other cancer antigens measurements, as reported for other tumor types [36, 37].